A Nutritional Formulation for Cognitive Performance in Mild Cognitive Impairment: A Placebo-Controlled Trial with an Open-Label Extension

J Alzheimers Dis. 2015;48(3):591-5. doi: 10.3233/JAD-150057.

Abstract

Thirty-four individuals with mild cognitive impairment were randomized for 6 months to a nutraceutical formulation (NF: folate, alpha-tocopherol, B12, S-adenosyl methioinine, N-acetyl cysteine, acetyl-L-carnitine) or indistinguishable placebo, followed by a 6-month open-label extension in which all individuals received NF. The NF cohort improved in the Dementia Rating Scale (DRS; effect size >0.7) and maintained baseline performance in CLOX-1. The placebo cohort did not improve in DRS and declined in CLOX-1, but during the open-label extension improved in DRS and ceased declining in CLOX-1. These findings extend prior studies of NF efficacy for individuals without cognitive impairment and with Alzheimer's disease.

Keywords: Aging; Alzheimer’s disease; cognitive performance; dementia; mild cognitive impairment; nutraceutical.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cognitive Dysfunction / diet therapy*
  • Cohort Studies
  • Dietary Supplements*
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Treatment Outcome